

i&i Prague


inventions | investments

**I&I
BIO**


Let your invention grow



ÚOCHB AV
CR
IOCB PRAGUE



IOCB Tech



i&i Prague

Public Research Institution

Institute of Organic Chemistry and Biochemistry (**IOCB**), part of the Czech Academy of Sciences

Royalties : ~ 100 M USD p.a.

Licensing partners:

Gilead Sciences

Novo Nordisk

SHINE Medical Technologies

Beckman Coulter

<https://www.uochb.cz/en>

Technology Transfer Office

IOCB Tech, private company
100% owned subsidiary of the **IOCB**
Exclusive services to IOCB

Drug Discovery focus

- > 14 Licensed technologies
- > 15 projects under incubation
- > 50 patent families

<https://www.iocbtech.cz/>

Biotech Incubator & Investor

i&i Prague, private company
100% owned subsidiary of **IOCB Tech**
Projects outside of IOCB

Biotechnology focus

Established in 2017


10 Startups directly invested, 1 Exit

13 Licenses sold






**Sep 2021: i&i Biotech Fund started
3 Startups invested**

<https://www.iniprague.com/>

Invested Startups:

 <p>Dracen Pharmaceuticals</p>	www.dracenpharma.com	Tumor-Directed Glutamine Antagonist
 <p>Elphogene</p>	www.elphogene.cz	Liquid biopsy technology for cancer diagnostics
 <p>DIANA BIOTECHNOLOGIES</p>	www.dianabiotech.com	Proprietary PCR-based technologies EXIT
 <p>PEP·Therapy</p>	www.pep-therapy.com	Innovative peptides for oncology

Invested Startups:

 LAM · X	www.lam-x.tech	Light-activated nanomaterials fighting infections
 CASINVENT	www.casinvent.com	Casein Kinase 1 inhibitors for cancer treatment
 XENO	www.xenocells.com	Yeast cell based biocomputing
 PerioTrap	periotrap.com	Curative treatment of periodontitis
 Sulfotools	en.sulfotools.com	Green peptide synthesis technology

Evaluation and Smart Money Investment:

- Projects are evaluated and supported by **Life Sciences professionals**
- **Peer to peer** review regarding the market need and the technology
- i&i Prague facilitates obtaining the **industry feedback and partnering** for most of the projects
- i&i Prague organizes **independent technology testing**, if applicable

Early phase project support, direct licensing:

Projects commercialized via
support of direct licensing

13 License agreements signed

- Example:

<https://www.uochb.cz/en/news/343/license-for-new-precision-test-for-antibodies-protecting-against-coronavirus>

PRESS RELEASE

License for new precision test for antibodies protecting against coronavirus

7 SEPTEMBER 2021

The [Institute of Biotechnology](#) (IBT) and the Institute of Organic Chemistry and Biochemistry (IOCB Prague), both part of the Czech Academy of Sciences, have signed a licensing agreement with the company Immunotech, a subsidiary of Beckman Coulter, for the manufacture and distribution of a newly developed coronavirus antibody IVD test. The new type of test can quickly determine levels of protective coronavirus antibodies and is thus different from most other tests, which only provide information on the level of total binding antibodies. It will make virus neutralization antibody testing, which is time consuming and costly, far simpler and more affordable. The new type of test should soon appear on the international market.

Collaboration with industrial partners:

- **i&i Prague offers:**
 - RISK SHARING. Thanks to previous successful projects, we can provide funding for early stages of development
 - Innovations and technologies resulting from fundamental academic research
 - Experiences and willingness to co-operate with Industrial partners
- **i&i Prague is looking for industrial partners** with a strong position in Pharma/Biotech, Diagnostics or Health Care Industry providing:
 - Brief Industry feedback evaluating the projects in early stages (non-confidential level)
 - Project co-development or other ways of supported development and partnering

Sep 2021: i&i Biotech Fund started

A unique biotech fund, [i&i Biotech Fund](#), supported by highly reputable institutions, strong track record, team of professionals and proprietary access to deal flow.

Fund Size: EUR 50 - 60M (1st closing € 45M)

Fund Term: 5+5+3 years (Exit in 5-8 years)

Geography: EU member states, focus on Central Europe (AT, CZ, DE, HU, PL, SK),

Sectors: Life Sciences and Biotech (Drug Discovery, Diagnostics, Medical Devices, Life Sciences Tools)

Stage of Investment: Seed -> Series A -> Series B follow up investment

Investment Size: up to EUR 2M per project and round

Fund Category: Technology Transfer seed investments

Fund Start: Q3 2021 (established 12.8.2021)

i& Biotech Fund Investors:

i&i Prague, a commercial subsidiary of **IOCB Tech** / IOCB

i&i Prague
inventions | investments

European Investment Fund (“EIF”)

 #Believe
InSmall
www.eif.europa.eu

Private investors (private and institutional)



The Fund is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.

Evaluation Process and Responsibilities:


i&i Prague

inventions | investments

- Evaluated/executed by i&i Prague
- Evaluation time: 4-6 months
- Shared responsibilities



- Evaluated/executed by i&i Biotech Fund



i&i Biotech Fund current status: Mar 2022

Since Sep 2021:

- **3 projects invested**





i&i Prague

inventions | investments

Let your invention grow